These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 25662413

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
    Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, Howarth D, Campbell F, Rhodes JM.
    Gut; 2011 Nov; 60(11):1520-6. PubMed ID: 21471566
    [Abstract] [Full Text] [Related]

  • 24. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.
    Palandri F, Polverelli N, Catani L, Sollazzo D, Romano M, Levorato M, Vianelli N.
    Am J Hematol; 2014 Nov; 89(11):1047-50. PubMed ID: 25103500
    [Abstract] [Full Text] [Related]

  • 31. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.
    Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR, Dutch HOVON 64 study group.
    Haematologica; 2015 Mar; 100(3):e90-2. PubMed ID: 25425692
    [No Abstract] [Full Text] [Related]

  • 32. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
    Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D.
    Am J Hematol; 2014 Jan; 89(1):41-6. PubMed ID: 24038066
    [Abstract] [Full Text] [Related]

  • 33. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.
    Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, Du X, Sun J, Zhou Z, Yan Z, Chen W, Wang W, Liu Q, Zeng Q, Gong Y, Yin J, Shen X, Ye B, Chen Y, Xu Y, Sun H, Cheng Y, Liu Z, Wang C, Yuan G, Zhang X, Li X, Cheng P, Guo X, Jiang Z, Yang F, Yang L, Luo C, Xiao T, Fu S, Yin H, Guo X, Xu Q, Fan S, Shi MM, Su W, Mei H, Yang R.
    Lancet Haematol; 2024 Aug; 11(8):e567-e579. PubMed ID: 38885672
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A, ADVANCE Investigator Study Group.
    Lancet; 2023 Nov 04; 402(10413):1648-1659. PubMed ID: 37778358
    [Abstract] [Full Text] [Related]

  • 36. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
    Auger S, Duny Y, Rossi JF, Quittet P.
    Br J Haematol; 2012 Aug 04; 158(3):386-98. PubMed ID: 22612239
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar 04; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
    Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand JM, Chiche L, Khellaf M, Bierling P, Roudot-Thoraval F, Godeau B, Michel M.
    Am J Hematol; 2013 Oct 04; 88(10):858-61. PubMed ID: 23798363
    [Abstract] [Full Text] [Related]

  • 40. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun 04; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.